Treatment Combining X-Irradiation and a Ribonucleoside Anticancer Drug, TAS106, Effectively Suppresses the Growth of Tumor Cells Transplanted in Mice

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 1, 2007, Pages 218-228

  Yasui, Hironobu ^a   Inanami, Osamu ^a   Asanuma, Taketoshi ^a   Iizuka, Daisuke ^a   Nakajima, Takayuki ^b   Kon, Yasuhiro ^a   Matsuda, Akira ^c   Kuwabara, Mikinori ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Osaka Prefecture University   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anticancer drug; Survivin; Transplanted tumor; X irradiation

Indexed keywords

HISTOLOGY; IMMUNOLOGY; PROTEINS; TRANSPLANTATION (SURGICAL); TUMORS; X RAYS;

ANTICANCER DRUGS; SURVIVINS; TRANSPLANTED TUMORS; X-IRRADIATION;

DRUG PRODUCTS;

3' ETHYNYLCYTIDINE; KI 67 ANTIGEN; RIBONUCLEOSIDE DERIVATIVE; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRAFT; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECTUM CARCINOMA; SCID MOUSE; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT; X IRRADIATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYTIDINE; DRUG EVALUATION, PRECLINICAL; FEMALE; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; STOMACH NEOPLASMS;

EID: 34247125161     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.12.061     Document Type: Article

References (35)

1. Montgomery J.A., Ananthan S., Parker W.B., et al. Antimetabolites. [series: ACS Professional Reference Book]. In: Foye W.O. (Ed). Cancer chemotherapeutic agents (1995), American Chemical Society, Washington DC 47-110
2. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3 (2002) 415-424
3. Matsuda A., and Sasaki T. Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci 95 (2004) 105-111
4. Sangar V.K., Cowan R., Margison G.P., et al. An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines. Br J Cancer 90 (2004) 542-548
5. Mason K.A., Milas L., Hunter N.R., et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44 (1999) 1125-1135
6. Grem J.L. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18 (2000) 299-313
7. Nam N.H., and Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 4 (2003) 159-179
8. McDonnell T.J., Meyn R.E., and Robertson L.E. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6 (1995) 53-60
9. Su L.N., and Little J.B. Prolonged cell cycle delay in radioresistant human cell lines transfected with activated ras oncogene and/or simian virus 40 T-antigen. Radiat Res 133 (1993) 73-79
10. Inanami O., Iizuka D., Iwahara A., et al. A novel anticancer ribonucleoside, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine, enhances radiation-induced cell death in tumor cells. Radiat Res 162 (2004) 635-645
11. Iizuka D., Inanami O., Matsuda A., et al. X irradiation induces the proapoptotic state independent of the loss of clonogenic ability in Chinese hamster V79 cells. Radiat Res 164 (2005) 36-44
12. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5 (2005) 231-237
13. Hattori H., Tanaka M., Fukushima M., et al. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39 (1996) 5005-5011
14. Shimamoto Y., Koizumi K., Okabe H., et al. Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2. Jpn J Cancer Res 93 (2002) 825-833
15. Maehara Y., Nakamura H., Nakane Y., et al. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann 73 (1982) 289-298
16. Azuma A., Matsuda A., Sasaki T., et al. 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: Antitumor effect and mechanism of action. Nucleosides Nucleotides Nucleic Acids 20 (2001) 609-619
17. Matsuda A., Fukushima M., Wataya Y., et al. A new antitumor nucleoside, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl) cytosine (ECyd), is a potent inhibitor of RNA synthesis. Nucleoside Nucleotide 18 (1999) 811-814
18. Takatori S., Kanda H., Takehara K., et al. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil. Cancer Chemother Pharmacol 44 (1999) 97-104
19. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
20. Shin S., Sung B.J., Cho Y.S., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
21. Schimmer A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 64 (2004) 7183-7190
22. Tomayko M.M., and Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24 (1989) 148-154
23. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3 (2003) 117-129
24. McGinn C.J., and Lawrence T.S. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11 (2001) 270-280
25. Siddik Z.H., Mims B., Lozano G., et al. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58 (1998) 698-703
26. Zhivotovsky B., Joseph B., and Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res 248 (1999) 10-17
27. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 (2004) 937-947
28. Jorgensen K., Holm R., Maelandsmo G.M., et al. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: Relationship with clinical outcome. Clin Cancer Res 9 (2003) 5325-5331
29. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
30. Valerie K., and Povirk L.F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22 (2003) 5792-5812
31. Rogakou E.P., Pilch D.R., Orr A.H., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273 (1998) 5858-5868
32. Rodel C., Haas J., Groth A., et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55 (2003) 1341-1347
33. Khanna K.K., Lavin M.F., Jackson S.P., et al. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 8 (2001) 1052-1065
34. Aldridge D.R., and Radford I.R. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 58 (1998) 2817-2824
35. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3 (2004) 513-519